Key facts
- It has raised $8.2M; the latest was Seed Round ($8.2M) in Sep 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for RxMapper
- ·The full record, as it builds
Funding rounds
No funding rounds for RxMapper are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RxMapper
Developer of a personalized medication monitoring platform designed to analyze DNA sequencing. The company's platform offers sequencing results of patients and identifies which drugs patients should be prescribed based on their DNA, which results in lower costs and improved health outcomes, enabling healthcare professionals to treat patients based on their personalized profile.
- Sector
- Healthcare
- HQ
- Scottsdale, AZ, United States
- Founded
- 2017
- Employees
- 23
- Website
- rxmapper.com/
- Ownership
- Privately Held (backing)
RxMapper doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RxMapper shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RxMapper in its N-PORT filings yet. We sweep new filings monthly.